Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment

Cancer Science

Volumn 102, Issue 11, 2011, Pages 2014-2021

  Tsai, Hui Jen ^a,b,c   Kobayashi, Seiichiro ^a   Izawa, Kiyoko ^a   Ishida, Takaomi ^a   Watanabe, Toshiki ^a   Umezawa, Kazuo ^d   Lin, Sheng Fung ^b,e   Tojo, Arinobu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KEIO UNIVERSITY   (Japan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCID MOUSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BONE MARROW; CELL LINE, TUMOR; CYCLOHEXANONES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, REPORTER; HUMANS; LUMINESCENT MEASUREMENTS; MICE; NEOPLASM PROTEINS; NF-KAPPA B; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RECOMBINANT FUSION PROTEINS; SPLEEN; STROMAL CELLS; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80055015759     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02039.x     Document Type: Article

References (44)

1. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
2. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev 1995; 9: 2723-35.
3. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
4. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammatory disorders and cancer. Cell 2006; 124: 823-35.
5. Rayet B, Gélinas C. Aberrant rel/nfκb genes and activity in human cancer. Oncogene 1999; 18: 6938-69.
6. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-6.
7. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-κB in hematologic malignancies. Cell Death Differ 2006; 13: 748-58.
8. Arima N, Molitor JA, Smith MR, Kim JH, Daitoku Y, Greene WC. Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of κB enhancer-binding proteins: evidence for a pretranslational component of regulation. J Virol 1991; 65: 6892-9.
9. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
10. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-74.
11. Cuní S, Pérez-Aciego P, Pérez-Chacón G et al. A sustained activation of PIK3/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18: 1391-400.
12. Bargou RC, Emmerich F, Krappmann D et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-9.
13. Hermans A, Heisterkamp N, von Linden M et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33-40.
14. Fainstein E, Marcelle C, Rosner A et al. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature 1987; 330: 386-8.
15. Westbrook CA, Hooberman AL, Spino C et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80: 2983-90.
16. Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Français de Cytogénétique Hématologique. Blood 1996; 87: 3135-42.
17. Gleissner B, Gökbuget N, Bartram CR et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536-43.
18. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
19. Wassmann B, Pfeifer H, Scheuring U et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002; 16: 2358-65.
20. Brave M, Goodman V, Kaminskas E et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008; 14: 352-9.
21. Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs 2008; 22: 59-69.
22. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-91.
23. Hofmann WK, Jones LC, Lemp NA et al. Ph+ acute lymphoblastic leukemia resistant to tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-2.
24. Liesveld JL, Rosell KE, Lu C et al. Acute myelogenous leukemia-microenvironment interactions: role of endothelial cells and proteasome inhibition. Hematology 2005; 10: 483-94.
25. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29: 448-57.
26. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J. Resistance to imatinib of Bcr/Abl p190 lymphoblastic leukemia cells. Cancer Res 2006; 66: 5387-93.
27. Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM. Constitutive NF-κB/Rel activation in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leuk Lymphoma 2004; 45: 1181-4.
28. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 12: 968-81.
29. BCR-ABL activates p65NF-κB). Oncogene 1997; 15: 2267-75.
30. Bai Y, Soda Y, Izawa K et al. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther 2003; 10: 1446-57.
31. Tojo A, Izawa K, Sekine R, Nagamura-Inoue T, Kobauashi S. Development of a unique in vitro and in vivo model system of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) with emphasis on cell to cell interaction (Abstract). Blood 2006; 108: 1845a.
32. Sekine R, Kitamura T, Tsuji T, Tojo A. Efficient retroviral transduction of human B-lymphoid and myeloid progenitors: marked inhibition of their growth by Pax5 transgene. Int J Hematol 2008; 87: 351-62.
33. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K. Inactivation of nuclear factor kappa B components by covalent binding of DHMEQ to specific cysteine residues. J Med Chem 2008; 51: 5780-8.
34. Inoue Y, Tojo A, Sekine R et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging 2006; 33: 557-65.
35. Matsumoto G, Namekawa J, Muta M et al. Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005; 11: 1287-93.
36. Naylor MS, Malik ST, Stamp GW, Jobling T, Balkwill FR. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer 1990; 26: 1027-30.
37. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71.
38. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784-7.
39. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274: 787-9.
40. Chauhan D, Uchiyama H, Akbarali Y et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996; 87: 1104-12.
41. Pikarsky E, Porat RM, Stein I et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
42. Wolf AM, Wolf D, Rumpold H et al. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 2005; 102: 13622-7.
43. Komori J, Marusawa H, Machimoto T et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008; 47: 888-96.
44. Feldhahn N, Henke N, Melchior K et al. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med 2007; 204: 1157-66.